Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr 4;100(14):687-688.
doi: 10.1212/WNL.0000000000207209.

Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Philipp Karschnia  1 , Kaj Rejeski  1   1   1 , Marion Subklewe  1 , Louisa von Baumgarten  1
Affiliations
Comment

Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Philipp Karschnia et al. Neurology. .

Erratum in

No abstract available

PubMed Disclaimer

Comment on

References

    1. Ursu R, Maillet D, Belin C, et al. Long-term neurologic safety in patients with B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy. Neurology. 2022;99(12):511-515. - PubMed
    1. Hoogland AI, Barata A, Logue J, et al. Change in neurocognitive performance among patients with non-hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2022;28(6):305.e1-305.e9. - PMC - PubMed
    1. Barata A, Hoogland AI, Kommalapati A, et al. Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma. Transpl Cell Ther. 2022;28(7):401.e1-401.e7. - PMC - PubMed
    1. Ruark J, Mullane E, Cleary N, et al. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl. 2020;26(1):34-43. - PMC - PubMed
    1. Karschnia P, Rejeski K, Winkelmann M, et al. Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells. Neurology. 2022;98(21):884-889. - PMC - PubMed

MeSH terms